Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Description

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.

Conditions

Alzheimer Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Houston

Baylor College of Medicine, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 55-85 years;
  • * Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
  • * Amyloid positivity on PET scan;
  • * Availability of a study partner.
  • * hospitalization in past 3 months;
  • * use of insulin medications;
  • * untreated thyroid disease;
  • * creatinine levels \>1.5 mg/dL;
  • * hemoglobin concentration \<11.0 g/dL;
  • * known liver disease, or AST/ALT level \>2x ULN;
  • * history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
  • * untreated depression or other severe psychiatric disorders;
  • * pregnancy or nursing (unlikely in this population)

Ages Eligible for Study

55 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Baylor College of Medicine,

Rajagopal V Sekhar, M.D., PRINCIPAL_INVESTIGATOR, Baylor College of Medicine

Study Record Dates

2026-12-31